Loading…

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

EGFR-specific tyrosine kinase inhibitors (TKIs), especially osimertinib, have changed lung cancer therapy, but secondary mutations confer drug resistance. Because other EGFR mutations promote dimerization-independent active conformations but L858R strictly depends on receptor dimerization, we herein...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports. Medicine 2023-08, Vol.4 (8), p.101142-101142, Article 101142
Main Authors: Marrocco, Ilaria, Giri, Suvendu, Simoni-Nieves, Arturo, Gupta, Nitin, Rudnitsky, Anna, Haga, Yuya, Romaniello, Donatella, Sekar, Arunachalam, Zerbib, Mirie, Oren, Roni, Lindzen, Moshit, Fard, Damon, Tsutsumi, Yasuo, Lauriola, Mattia, Tamagnone, Luca, Yarden, Yosef
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:EGFR-specific tyrosine kinase inhibitors (TKIs), especially osimertinib, have changed lung cancer therapy, but secondary mutations confer drug resistance. Because other EGFR mutations promote dimerization-independent active conformations but L858R strictly depends on receptor dimerization, we herein evaluate the therapeutic potential of dimerization-inhibitory monoclonal antibodies (mAbs), including cetuximab. This mAb reduces viability of cells expressing L858R-EGFR and blocks the FOXM1-aurora survival pathway, but other mutants show no responses. Unlike TKI-treated patient-derived xenografts, which relapse post osimertinib treatment, cetuximab completely prevents relapses of L858R tumors. We report that osimertinib's inferiority associates with induction of mutagenic reactive oxygen species, whereas cetuximab's superiority is due to downregulation of adaptive survival pathways (e.g., HER2) and avoidance of mutation-prone mechanisms that engage AXL, RAD18, and the proliferating cell nuclear antigen. These results identify L858R as a predictive biomarker, which may pave the way for relapse-free mAb monotherapy relevant to a large fraction of patients with lung cancer.
ISSN:2666-3791
2666-3791
DOI:10.1016/j.xcrm.2023.101142